MA32013B1 - Derives de l'acide phenylacetique utiles comme modulateurs de l'inflammation - Google Patents

Derives de l'acide phenylacetique utiles comme modulateurs de l'inflammation

Info

Publication number
MA32013B1
MA32013B1 MA33012A MA33012A MA32013B1 MA 32013 B1 MA32013 B1 MA 32013B1 MA 33012 A MA33012 A MA 33012A MA 33012 A MA33012 A MA 33012A MA 32013 B1 MA32013 B1 MA 32013B1
Authority
MA
Morocco
Prior art keywords
inflammation
acid derivatives
phenylacetic acid
modulating agent
cycloalkyl
Prior art date
Application number
MA33012A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Mark Grillo
An-Rong Li
Jiwen Liu
Julio C Medina
Yongli Su
Yingcai Wang
Janan Jona
Alan Allgeier
Jacqueline Milne
Jerry Murry
Joseph F Payack
Thomas Storz
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA32013B1 publication Critical patent/MA32013B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/04Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
MA33012A 2007-12-19 2010-07-14 Derives de l'acide phenylacetique utiles comme modulateurs de l'inflammation MA32013B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US843307P 2007-12-19 2007-12-19
PCT/US2008/013833 WO2009085177A1 (en) 2007-12-19 2008-12-18 Phenyl acetic acid derivatives as inflammation modulators

Publications (1)

Publication Number Publication Date
MA32013B1 true MA32013B1 (fr) 2011-01-03

Family

ID=40564868

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33012A MA32013B1 (fr) 2007-12-19 2010-07-14 Derives de l'acide phenylacetique utiles comme modulateurs de l'inflammation

Country Status (20)

Country Link
US (1) US8183293B2 (enExample)
EP (1) EP2231595B1 (enExample)
JP (1) JP5437267B2 (enExample)
KR (1) KR20100102668A (enExample)
CN (1) CN101903338A (enExample)
AR (1) AR071279A1 (enExample)
AU (1) AU2008343924B2 (enExample)
BR (1) BRPI0821197A2 (enExample)
CA (1) CA2707789A1 (enExample)
CL (1) CL2008003832A1 (enExample)
CO (1) CO6321234A2 (enExample)
CR (1) CR11572A (enExample)
EA (1) EA201001029A1 (enExample)
ES (1) ES2471919T3 (enExample)
IL (1) IL206069A0 (enExample)
MA (1) MA32013B1 (enExample)
PE (1) PE20091526A1 (enExample)
TN (1) TN2010000223A1 (enExample)
TW (1) TW200940051A (enExample)
WO (1) WO2009085177A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
EP2790696A1 (en) 2011-12-16 2014-10-22 Atopix Therapeutics Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
US9974759B2 (en) * 2013-05-31 2018-05-22 Indiana University Research And Technology Corporation Beta 2 adrenoceptor antagonists for treating orthostatic hypotension
EP4420734A3 (en) 2015-02-13 2024-11-06 Institut National de la Santé et de la Recherche Médicale Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
SI3433234T1 (sl) 2016-03-22 2022-01-31 Merck Sharp & Dohme Corp. Alosterični modulatorji nikotinskih acetilholinskih receptorjev
ES2733477T3 (es) * 2017-07-04 2019-11-29 Fis Fabbrica Italiana Sintetici Spa Procedimiento eficaz para la preparación de sitagliptina a través de una preparación muy eficaz del intermedio ácido 2,4,5-trifluorofenilacético

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8704158D0 (en) 1987-02-23 1987-04-01 Wellcome Found Substituted hydantoin compounds
US5849780A (en) 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
JP3894949B2 (ja) 1993-06-30 2007-03-22 ザ、ウェルカム、ファンデーション、リミテッド 抗アテローム性動脈硬化症ジアリール化合物
US5545669A (en) * 1994-06-02 1996-08-13 Adams; Jerry L. Anti-inflammatory compounds
ATE223899T1 (de) * 1994-12-20 2002-09-15 Hoffmann La Roche Aryl-und hetaryl-sulfonamid derivate, deren herstellung und deren verwendung als endothelin- antagonisten
US6008234A (en) * 1996-09-12 1999-12-28 Berlex Laboratories, Inc. Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants
WO1998011094A1 (en) 1996-09-12 1998-03-19 Schering Aktiengesellschaft Benzamidine derivatives substituted by cyclic amino acid or cycl ic hydroxy acid derivatives and their use as anti-coagulants
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
JPH11202458A (ja) 1998-01-16 1999-07-30 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
US5929250A (en) 1997-01-23 1999-07-27 Smithkline Beecham Corporation IL-8 receptor antagonists
EP1076641A1 (en) 1998-04-29 2001-02-21 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
AR023659A1 (es) 1998-09-18 2002-09-04 Vertex Pharma Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
TR200102561T2 (tr) 1999-03-01 2002-02-21 Pfizer Products Inc. Tiroid alıcı ligantları olarak oksamik asitler ve türevleri
JP3828364B2 (ja) 1999-03-10 2006-10-04 塩野義製薬株式会社 [2.2.1]および[3.1.1]ビシクロ骨格を有するpgd2/txa2両受容体拮抗性医薬組成物
EP1211513B1 (en) 1999-08-23 2006-01-04 BML, Inc. Method of identifying modulators of prostaglandin d2 receptors
US6531291B1 (en) * 1999-11-10 2003-03-11 The Trustees Of Columbia University In The City Of New York Antimicrobial activity of gemfibrozil and related compounds and derivatives and metabolites thereof
EP1255750A1 (en) 2000-02-01 2002-11-13 Millenium Pharmaceuticals, Inc. INDOLE AND BENZIMIDAZOLE INHIBITORS OF FACTOR Xa
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
US7084136B2 (en) 2000-06-02 2006-08-01 Shionogi & Co., Ltd. Drug composition antagonistic to both PGD2/TXA2 receptors
US6878522B2 (en) * 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
WO2002045718A1 (en) 2000-12-08 2002-06-13 Institut Pasteur De Lille Use of active compounds capable of modulating the intracellular pathway triggered by the dp receptor in langerhans cells
CA2433100A1 (en) 2000-12-27 2002-07-04 Helmut Haning Indole derivatives as ligands of thyroid receptors
WO2002094830A2 (en) 2001-05-23 2002-11-28 Merck Frosst Canada & Co. DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-a]-INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
PL368129A1 (en) 2001-08-09 2005-03-21 Ono Pharmaceutical Co, Ltd. Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
NZ535309A (en) 2002-03-19 2006-05-26 Ono Pharmaceutical Co Carboxylic acid compounds and drugs containing the compounds as the active ingredient
WO2003097042A1 (en) 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Pgd2 receptor antagonist
US7534897B2 (en) 2002-05-16 2009-05-19 Shionogi & Co., Ltd. Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism
GB2388540A (en) 2002-05-17 2003-11-19 Bayer Ag New use of Ramatroban
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
GB0224557D0 (en) 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
CA2511214C (en) * 2002-12-20 2012-12-18 Tularik, Inc. Asthma and allergic inflammation modulators
WO2005054176A1 (en) 2003-11-25 2005-06-16 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
WO2007039736A1 (en) * 2005-10-06 2007-04-12 Astrazeneca Ab Novel compounds
CA2672631A1 (en) * 2006-12-15 2008-06-19 Glaxo Group Limited Benzamide derivatives as ep4 receptor agonists
US7960567B2 (en) * 2007-05-02 2011-06-14 Amgen Inc. Compounds and methods useful for treating asthma and allergic inflammation
WO2011014588A2 (en) 2009-07-31 2011-02-03 Amira Pharmaceuticals, Inc. Dermal formulations of dp2 receptor antagonists
WO2011014587A2 (en) 2009-07-31 2011-02-03 Amira Pharmaceuticals, Inc. Ophthalmic pharmaceutical compositions of dp2 receptor antagonists

Also Published As

Publication number Publication date
CL2008003832A1 (es) 2010-03-26
AU2008343924A1 (en) 2009-07-09
KR20100102668A (ko) 2010-09-24
AU2008343924B2 (en) 2013-01-17
CN101903338A (zh) 2010-12-01
JP5437267B2 (ja) 2014-03-12
TN2010000223A1 (en) 2011-11-11
CA2707789A1 (en) 2009-07-09
WO2009085177A1 (en) 2009-07-09
CR11572A (es) 2010-08-13
JP2011507847A (ja) 2011-03-10
EP2231595B1 (en) 2014-04-23
US8183293B2 (en) 2012-05-22
BRPI0821197A2 (pt) 2015-06-16
AR071279A1 (es) 2010-06-09
EA201001029A1 (ru) 2011-06-30
EP2231595A1 (en) 2010-09-29
PE20091526A1 (es) 2009-11-01
CO6321234A2 (es) 2011-09-20
TW200940051A (en) 2009-10-01
US20090275659A1 (en) 2009-11-05
ES2471919T3 (es) 2014-06-27
AU2008343924A2 (en) 2011-02-17
IL206069A0 (en) 2010-11-30

Similar Documents

Publication Publication Date Title
MA34169B1 (fr) Dérivés d'acide 1-amino-2-cyclopropyléthylboronique
MA32013B1 (fr) Derives de l'acide phenylacetique utiles comme modulateurs de l'inflammation
EP2040713A4 (en) Gallic acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or disorders
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
TN2009000138A1 (fr) Biaryl-ether-urees
MA35576B1 (fr) Nouveaux composés
MA41238A (fr) Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit
MA28077A1 (fr) Derives d'isoquinilone 1,4-disubstitues en tant qu'inhibiteurs de raf-kinase utiles pour le traitement de maladies proliferantes
MA32729B1 (fr) Derives d'acide 1-amino-2-cyclobutylethylboronique
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
ATE538099T1 (de) 2-ä1-phenyl-5-hydroxy-4-alpha-methyl- hexahydrocyclopentaäfüindazol-5- ylüethylphenylderivate als glucocorticoidrezeptorliganden
MA31894B1 (fr) Composes organiques
EP1592689A4 (en) 3-AMINO-4-PHENYLBUTANEAN DERIVATIVES AS DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
EP1589969A4 (en) 3-AMINO-4-PHENYLBUTANEAN DERIVATEALS DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
CY1110969T1 (el) 5-υποκατεστημενα-2-φαινυλαμινο-βενζαμιδια ως αναστολεiς μεκ
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
MA32471B1 (fr) Composés de borates esters et compositions pharmaceutiques contenant des composés
MA29330B1 (fr) Antagonistes de recepteur de pgd2 pour le traitement des maladies inflammatoires.
TN2014000147A1 (fr) Derives de (4-phenylimidazol-2-yl) ethylamine utiles comme modulateurs de canal sodique
EA201001821A1 (ru) Производные триазола, полезные для лечения заболеваний
MA32035B1 (fr) Composes tricycliques servant de modulateurs de synthese de tnf-alpha et d'inhibiteurs de pde4
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
EA200870218A1 (ru) Замещенные имидазольные производные, композиции и способы применения в качестве ингибиторов ртразы
MA31117B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes